To induce specific antitumor adaptive immune responses, tumor-derived antigens must not only be taken up by innate immune cells; they must also be efficiently processed and cross-presented to CD8+ T cells in the presence of a costimulatory signal. The gene discussed is CD8A; the disease is neoplasm.